Provided by Tiger Fintech (Singapore) Pte. Ltd.

Prothena Corp PLC

5.89
-0.1800-2.97%
Volume:132.63K
Turnover:793.69K
Market Cap:317.04M
PE:-2.87
High:6.14
Open:6.14
Low:5.87
Close:6.07
Loading ...

Cantor Fitzgerald Keeps Their Hold Rating on Prothena (PRTA)

TIPRANKS
·
20 Jun

Prothena up 3% after announcing corporate restructuring, cash burn update

TIPRANKS
·
19 Jun

Prothena sees 2025 net cash burn from operating/investing at $170M-$178M

TIPRANKS
·
19 Jun

Prothena Chief Regulatory Officer Karp, Chief People Officer Ford to depart

TIPRANKS
·
19 Jun

Prothena Corp Public Ltd Co - Announces 63% Workforce Reduction - SEC Filing

THOMSON REUTERS
·
19 Jun

Prothena Corporation Announces 63% Workforce Reduction Amidst Strategic Reorganization

Reuters
·
19 Jun

BRIEF-Prothena announces corporate restructuring

Reuters
·
19 Jun

Prothena Corporation Announces Phase 3 Advancement of Prasinezumab for Early-Stage Parkinson's Disease

Reuters
·
19 Jun

Prothena Corporation Plc - May Receive up to $105 Mln in 2026

THOMSON REUTERS
·
19 Jun

Prothena Announces Corporate Restructuring

THOMSON REUTERS
·
19 Jun

Prothena Corporation Plc - Announces 63% Workforce Reduction

THOMSON REUTERS
·
19 Jun

Prothena: Expects Discontinuation of Birtamimab Development Will Result in Approximate Decrease of $96 Mln (Midpoint) in Annualized Net Cash Burn

THOMSON REUTERS
·
19 Jun

Oppenheimer Sticks to Their Hold Rating for Prothena (PRTA)

TIPRANKS
·
16 Jun

Prothena Corporation Announces Advancement of Prasinezumab into Phase III Trials for Early-Stage Parkinson's Disease

Reuters
·
16 Jun

Buy/Sell: Wall Street's Top 10 Stock Calls This Week

The Fly
·
01 Jun

Prothena Cut to Underperform From Neutral by B of A Securities

Dow Jones
·
29 May

Prothena Corporation Plc : Bofa Global Research Cuts to Underperform From Neutral; Cuts Price Objective to $4 From $22

THOMSON REUTERS
·
28 May

BofA Securities Downgrades Prothena to Underperform From Neutral, $4 Price Target

MT Newswires Live
·
28 May

Prothena downgraded to Underperform at BofA after birtamimab fails in clinic

TIPRANKS
·
28 May

Update: Prothena Shares Fall, Stock Downgraded by Multiple Research Firms After Birtamimab Development Discontinued

MT Newswires Live
·
28 May